Blow For Pfizer As UK's NICE Rejects Oxbryta For Sickle Cell Disease

Oxbryta is a highly lauded, first-in-class treatment for sickle cell anemia, a serious and lifelong health condition that can cause pain, infections, organ damage and strokes. But preliminary draft guidance from England’s HTA body says the product is not an acceptable use of National Health Service resources.